Amgen Drug Combined with Immunotherapy Extends Survival in Lung Cancer Trial
The 563-patient trial found the combination cut death risk by 58% and lifted median survival to 21.1 months, researchers said.
- Data released Saturday shows that adding Amgen's immunotherapy Imdelltra to AstraZeneca's Imfinzi reduced death risk by 58% in extensive-stage small cell lung cancer patients, extending median survival to 21.1 months versus 12.7 months for Imfinzi alone.
- The drugs work together by removing immune system brakes and binding to DLL3 and CD3 proteins to recruit T cells directly to tumor cells, creating an "indispensable backbone therapy," according to Amgen CMO Paul Burton.
- Presented at the European Society for Medical Oncology meeting in Madrid, the 563-patient trial recorded serious side effects in 20.9% of dual therapy patients compared with 10.8% receiving Imfinzi alone.
- Dr. Paul Burton stated the data could "transform the standard of care," potentially converting this aggressive cancer into a chronic disease, while patient Kate Brenan called the evolution "a good thing for the patients."
- Analysts project annual sales for Imdelltra could exceed $2.5 billion by 2030, as Amgen emphasizes that giving the drug earlier in treatment may meaningfully alter the disease trajectory for this notoriously difficult condition.
11 Articles
11 Articles
Amgen Reports Combo Cuts Lung Cancer Death Risk 58%
A Phase 3 trial found that adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small cell lung cancer reduced the risk of death by 58%, with median survival of 21.1 months versus 12.7 months on Imfinzi alone. The combination also delayed disease progression, though serious treatment-related side effects were more common than with Imfinzi alone. · 15 sources across the spectrum on IJR News.
Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial
A Phase 3 trial involving 563 patients found that combining tarlatamab with immunotherapy extended median survival from 12.7 to 21.1 months; researchers hailed the results at a Madrid oncology conference, although serious side effects and treatment costs remain concerns
Amgen drug combined with immunotherapy extends survival in lung cancer trial
By Deena Beasley Oct 24 (Reuters) - Amgen's Imdelltra used in combination with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% compared to the Astra drug alone in patients with extensive-stage small cell lung cancer, according to d...
Almost 80% of patients treated with a combination of tarlatamb and durvalumab were still alive every year, compared to 53% with durvalumab monotherapy, and progression-free survival increased by more than three times
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients more...
Coverage Details
Bias Distribution
- 43% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
